Home > Healthcare > Pharmaceuticals > Clinical Nutrition > Enteral Feeding Formulas Market

Enteral Feeding Formulas Market Trends

Report ID: GMI12131
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Enteral Feeding Formulas Market Trends

Advancements in medical nutrition, particularly the development of specialized formulas for oncology and inflammatory bowel disease treatment, which was valued at USD 22.6 billion in 2023, are driving market expansion.
The growing number of patients and elderly individuals requiring enteral feeding due to chronic illnesses, surgeries, and critical care is fueling market growth. According to the World Health Organization, by 2030, one in six people globally are expected to be aged 60 or older, with the population in this age group rising from 1 billion in 2020 to 1.4 billion. By 2050, the number of people aged 60 and over is projected to double to 2.1 billion. Additionally, the population aged 80 and older is expected to triple from 2020 to 2050, reaching 426 million. This demographic shift indicates a potential increase in the demand for enteral nutrition solutions.
Enhancements in delivery systems, including smart feeding pumps and user-friendly packaging for enteral formulas, are improving patient compliance and caregiver convenience. These improvements are likely to contribute to better patient outcomes and increased adoption of enteral nutrition therapies.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global enteral feeding formulas industry was valued at approximately USD 7 billion in 2023 and is estimated to grow at a 7.1% CAGR from 2024 to 2032, driven by the increasing prevalence of medical conditions requiring enteral nutrition.

The standard formulas market generated USD 3.6 billion in 2023 and is expected to grow due to their widespread adoption across diverse patient groups and cost-effectiveness.

The U.S. enteral feeding formulas industry was valued at USD 2.8 billion in 2023 and is projected to grow at a CAGR of 7.2% over the forecast period, supported by innovations in product formulations such as lactose-free and gluten-free options.

Key players in the industry include Abbott Laboratories, B. Braun Melsungen AG, Baxter International, Danone S.A., Fresenius Kabi, Functional Formularies, Hormel Health Labs, Kate Farms, Medtrition, and Meiji Holdings.